- Agnieszka Małecka1⇑,
- Gunhild Trøen1,
- Anne Tierens2,
- Ingunn Østlie1,
- Jędrzej Małecki3,
- Ulla Randen1,
- Sigbjørn Berentsen4,
- Geir E. Tjønnfjord5 and
- Jan M.A. Delabie2
- 1Department of Pathology, Oslo University Hospital, Norway
- 2Laboratory Medicine Program, University Health Network and University of Toronto, ON, Canada
- 3Department of Biological Sciences, University of Oslo, Norway
- 4Department of Research and Innovation, Haugesund Hospital, Helse Fonna, Haugesund, Norway
- 5Department of Haematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway
- Correspondence: /
Immunoglobulin heavy chain (IGH) and light chain gene sequences of 27 patients with primary cold agglutinin disease (CAD) were studied to find features explaining the heterogeneity of clinical presentation and disease activity.
CAD is a hemolytic anemia mediated by monoclonal IgM anti-I autoantibodies. CAD represents 15% of all cases of autoimmune hemolytic anemia with an incidence of 1×10−6 per year. Previously, we demonstrated that CAD is caused by a low-grade clonal B-cell lymphoproliferative disease of the bone marrow with a typical histology that is different from lymphoplasmacytic lymphoma and, accordingly, does not display the MYD88 L265P mutation.1 Almost all patients display circulating monoclonal antibodies encoded by the IGH gene V4-34. The framework region 1 (FR1) of IGHV4-34 encodes Gln6–7 (QW) and Ala24-Val25-Tyr26 (AVY) sequences that determine I antigen-binding.2 IGHV4-34, as opposed to other IGHV4 family genes, has a unique N-glycosylation sequon Asn-X-Ser/Thr located within the complementarity-determining region 2 (CDR2). Inactivation of this sequon by somatic hypermutation (SHM) might increase the accessibility of the antigen-binding pocket.3 Hitherto, the immunoglobulin (IG) light chain usage in CAD has not been systematically studied.
We studied IGH and IG light chain gene sequences of 27 CAD patients. Productive IGHV4-34 gene rearrangements were identified in 81% (22/27) of patients (Table 1 and Online Supplementary Table S1). In 4 patients (15%), productive rearrangements could not be identified, whereas a productive IGHV3-23 gene rearrangement was detected in 1 patient (CAD-5). No significant homology of CDR3 regions was found between IGHV sequences. In all but one case (CAD-7), the AVY sequence, required for I antigen-binding, was conserved. In CAD-7, the AVY was mutated to VVY (Figure 1A), replacing alanine (A) with valine (V), that has similar biophysical properties. The N-glycosylation sequence within the IGH CDR2 region, also known to affect I antigen-binding, was mutated in 8 patients (36.5%), whereas no mutations were present in 14 patients. However, in 6 of the latter patients mutations in flanking residues were detected (27%) (Figure 1A; Table 1 and Online Supplementary Table S1). Mutations flanking the N-glycosylation region are also known to modulate glycosylation efficacy.3 A mutation hotspot in IGH FR3 was identified at the germline amino acid sequence Lys90-Leu91-Ser92 (KLS) (Figure 1A). All but 3 patients showed mutations in this region with 7/22 (32%) revealing 1 mutation, 11/22 (50%) 2 mutations and 1/22 (4.5%) 3 mutations (Table 1 and Online Supplementary Table S1). Clonal rearrangement of the immunoglobulin κ (IGK)V3-20 gene was detected in 16/27 (59%) of patients, clonal rearrangement of the IGKV3-15 gene was identified in 4/27 (15%) of patients, whereas other IG light chain genes were rearranged in 4/27 (15%) of patients (Table 1 and Online Supplementary Table S1). In 3/27 (11%) of patients clonal IG light chain gene rearrangements could not be demonstrated. Of interest, 9 of the patients with IGKV3-20 rearrangement displayed highly homologous CDR3 regions (Figure 2). IGHV and IGKV genes were variably mutated. MYD88 L265P mutation, typical for lymphoplasmacytic lymphoma, was not detected in any of the analyzed samples.
We found lower hemoglobin levels at diagnosis to be correlated with inactivating mutations of the N-glycosylation site located within IGH CDR2 (P=0.036) (Table 1). The N-glycosylation site is located within the antigenbinding pocket (Figure 1B). It has previously been suggested that an intact N-glycosylation site diminishes specific binding of the antigen-binding site of the antibody.3 Thus, the observation that patients with mutations at the N-glycosylation site had more severe anemia is consistent with I antigen-binding by the antibody antigen-binding site, as previously demonstrated by functional tests.2,4,5 A recent study also showed that the reintroduction of the N-glycosylation site in mutated IGHV4-34 caused a moderate (20%), but reproducible, impairment of B cell survival in cells that are dependent on the binding of the B-cell receptor to auto-antigens.6 SHM of the site, rendering it non-functional, might thus be advantageous for cell survival in neoplastic B cells that have escaped the normal immune control of autoreactivity. SHM of the N-glycosylation site in IGHV4-34 in normal memory B cells may play a similar role, although in those cells increased accessibility of the antigen-binding site to foreign antigens instead of I antigen is likely important for cell selection and survival.3
We found that the KLS amino acid sequence in FR3 of IGHV4-34 was mutated in almost all CAD patients (Figure 1A), and that an increased number of mutations significantly correlated with reduced hemoglobin levels at diagnosis (P=0.030) (Table 1). We also investigated mutations in this sequence in previously published sequences as well as our own database and found it often mutated, most frequently at Ser (S), in normal B cells as well as in B-cell lymphoma.3,7 This region seems to be highly conserved in IGHV4 family germline genes (Online Supplementary Figure S1). Analysis of the protein structure8 shows that KLS amino acids are located at the protein surface, relatively close to the antigen-binding region at a distance similar to the I antigen-binding AVY hydrophobic patch (Figure 1B). The KLS amino acid sequence is coded by a DNA sequence containing five known mutation hotspot motifs characteristic for SHM (Online Supplementary Figure S2).9 Clinical data suggest that a mutated KLS sequence might enhance I antigen-binding since the number of mutations in this sequence correlated with lower hemoglobin levels at diagnosis. Of interest, combining the mutation levels in N-glycosylation and KLS sequences gave a very strong correlation with decreased hemoglobin levels at diagnosis (P=0.0055) (Table 1), stressing the importance of these sites for I antigen-binding. There is no significant correlation between the overall SHM rate of IGHV and hemoglobin levels (P=0.21).
Few data have been published with regard to IGKV gene usage in CAD. Reanalysis of published data shows that the IGKV3-20 gene was used in most published CAD cases (12/16) (see Online Supplementary Data). We also reanalyzed data from Li et al.,4 who studied the role of the IG light chain in determining antibody specificity by generating combinatorial antibodies (Online Supplementary Table S2). Antibodies with IG light chains obtained from CAD patients bound I antigen by ELISA testing, with IGKV3-20 showing the strongest binding. When combined with IGHV4-34, IG light chains obtained from other individuals without CAD showed I antigen-binding exclusively when encoded by IGKV3-20 (see Online Supplementary Data). Our study, including the reanalysis of older published data, shows that the IG light chain is encoded by the IGKV3-20 or IGKV3-15 gene in more than 80% of patients, indicating that the light chain equally contributes to I antigen-binding. The highly restricted usage of light chain genes provides a rationale for using anti-immunoglobulin light chain vaccination as part of the treatment for CAD, as has been proposed for treating other B-cell lymphomas.10
There was a strong correlation between younger age at diagnosis and the presence of a highly homologous or stereotyped IGKV3-20 CDR3 region (P=0.011) (Table 1). Nine of the patients showed almost identical amino acid sequences of IGKV3-20 CDR3 (Figure 2). This homology is a strong argument for antigen selection as a primary cause of CAD. Whether this is I antigen or a related exogenous, perhaps bacterial, antigen is unknown. Since both IGHV4-34 and IGKV3-20 are known to encode for antibodies that bind infectious antigens, it is possible that infection is the source of antigen selection that triggers CAD.11 The highly homologous antibody gene sequences found in younger patients indicate that antigen selection in these patients may be different than that in other patients. Additionally, a lower mutation rate of IGKV3-20 was also correlated with younger age at diagnosis (P=0.012) (Table 1).
Although CAD antibodies are almost exclusively encoded by IGHV4-34, 1 patient in the study (CAD-5) showed cold agglutinins encoded by IGHV3-23 and IGKV3-20. This patient displayed typical clinical characteristics of CAD. Previously, it was shown that anti-I cold agglutinins may also be encoded by IGHV3 family genes.12 Marks et al.13 isolated human antibody using IGHV3-23 with specificity against I antigen.
The previous finding by our group of the absence of MYD88 L265P mutation in CAD-associated lymphoproliferative bone marrow disease1 has recently been questioned in a review article.14 MYD88 L265P mutation is detected in more than 90% of lymphoplasmacytic lymphoma.15 However, our present findings in a large number of CAD patients confirm the absence of MYD88 L265P mutation in bone marrow samples using a sensitive technique. The absence of the mutation in primary CAD is a strong argument against the diagnosis of lymphoplasmacytic lymphoma in these patients.
In conclusion, our data show that in addition to IGHV, immunoglobulin light chain V usage is highly restricted in CAD. Our data indicate that multiple regions within the immunoglobulin heavy chain as well as the immunoglobulin light chain, contribute to I antigen-binding and may determine the clinical phenotype of the disease. Of practical consequence, the highly restricted usage of IGKV320 provides a rationale to include vaccination with IGKV3-20 proteins in novel clinical trial designs. IGKV320 proteins are known to be immunogenic and are being considered for treatment in other lymphoproliferative diseases.10
The authors would like to thank the South-Eastern Norway Regional Health Authority and the Norwegian Cancer Society for supporting this study.
Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.
- Copyright© Ferrata Storti Foundation